• 1
    Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, et al. Compensated cirrhosis: natural history and prognostic factors. HEPATOLOGY 1987; 7: 122-128.
  • 2
    Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992; 117: 215-220.
  • 3
    Silk AW, McTeague KM. Reexamining the physical examination for obese patients. JAMA 2011; 305: 193-194.
  • 4
    Sola E, Gines P. Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. J Hepatol 2010; 53: 1135-1145.
  • 5
    Llach J, Gines P, Arroyo V, Rimola A, Tito L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94: 482-487.
  • 6
    Pariente EA, Bataille C, Bercoff E, Lebrec D. Acute effects of catopril on systemic hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology 1985; 88: 1255-1259.
  • 7
    Gines P, Angeli P, Lenz K, Moller S, Moore K, Moreau R, et al. EASL clinical practice guideline on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome. J Hepatol 2010; 53: 397-417.
  • 8
    Serste T, Melot C, Francoz C, Durand F, Rautou P-E, Valla D, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. HEPATOLOGY 2010; 52: 1017-1022.
  • 9
    Serste T, Francoz C, Durand F, Rautou P-E, Melot C, Valla D, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol 2011; 55: 794-799.
  • 10
    Runyon BA, Greenblatt M, Ming RHC. Hepatic hydrothorax is a relative contraindication to chest tube insertion. Arch Intern Med 1986; 81: 566-567.
  • 11
    Orman ES, Lok ASF. Outcomes of patients with chest tube insertion for hepatic hydrothorax. Hepatol Int 2009; 3: 582-586.
  • 12
    Baltz JG, Argo CK, Al-Osaimi AM, Northup PG. Mortality after percutaneous endoscopic gastrostomy in patients with cirrhosis: a case series. Gastrointest Endosc 2010; 72: 1072-1075.
  • 13
    Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomized, double-blind controlled study. Lancet 2007; 370: 1915-1922.
  • 14
    Heydtmann M, Macdonald B, Lewsey J, Masson N, Cunningham L, Irnazarow AM, et al. The GABA-B agonist baclofen improves alcohol consumption, psychometrics and may have an effect on the hospital admission rates of patients with alcoholic liver disease. HEPATOLOGY 2012; 56: 1091A.
  • 15
    Hernandez AF, Greiner MA, Fonarow GC, Hammill BG, Heidenreich PA, Yancy CW, et al. Relationship between early physician follow-up and 30-day redmission among Medicare beneficiaries hospitalized for heart failure. JAMA 2010; 303: 1716-1722.
  • 16
    El-Bokl MA, Senousy BE, El-Karmouty KZ, Mohammed IE, Mohammed SM, Shabana SS, Shakaby H. Spot urine sodium for assessing dietary sodium restriction in cirrhotic ascites. World J Gastroenterol 2009; 15: 3631-3635
  • 17
    Wong F, Watson H, Gerbes A, Vilstrup H, Badalamenti S, Bernardi M, et al. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut 2012; 61: 108-116.
  • 18
    Singh V, Dhungana SP, Singh B, Vijayverghia R, Nain CK, Sharma N, et al. Midodrine in patients with cirrhosis and refractory ascites: a randomized pilot study. J Hepatol 2012; 56: 348-354.
  • 19
    Bernardi M, Carceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. HEPATOLOGY 2012; 55: 1172-1181.
  • 20
    Fernandez J, Acevedo J, Castro M, Garcia O, Rodriguez de Lope C, Roca D, et al. Prevalence and risk factors of infections by resistant bacteria in cirrhosis: a prospective study. HEPATOLOGY 2012; 55: 1551-1561.
  • 21
    Ariza X, Castellote J, Lora-Tamayo J, Girbau A, Salord S, Rota R, et al. Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare, and nosocomial spontaneous bacterial peritonitis. J Hepatol 2012; 56: 825-832.
  • 22
    Runyon BA. Changing flora of bacterial infections in patients with cirrhosis. Liver Int 2010; 30: 1245-1246.
  • 23
    Verna EC, Brown RS, Farraud E, Pichardo EM, Forster CS, Sola-Del Valle DA, et al. Urinary neutrophil gelatinase associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci 2012; 57: 2362-2370.
  • 24
    Fagundes C, Pepin M-N, Guevara M, Barreto R, Casals G, Sola E, et al. Urinary neutrophil gelatinase-associated lipocalin as a biomarker in the differential diagnosis of impairment of kidney function in cirrhosos. J Hepatol 2012; 57: 267-273.
  • 25
    Gluud LL, Christensen K, Christensen E, Krag A. Systemic review of randomized trials of vasoconstrictor drugs for hepatorenal syndrome. HEPATOLOGY 2010; 51: 576-584.
  • 26
    Sarin SK, Sharma P. Terlipressin: an asset for hepatologists. HEPATOLOGY 2011; 54: 724-728.